News | January 05, 2023
Biocytogen and Hansoh Pharma announce an antibody license agreement
Biocytogen will provide a license to Hansoh Pharma for their selected fully human antibody molecules
Biocytogen will provide a license to Hansoh Pharma for their selected fully human antibody molecules
If approved, the vaccine could help simplify the meningococcal vaccination schedule and provide the broadest serogroup coverage of any meningococcal vaccine
Ryzneuta is a novel dimeric G- CSF long-acting fusion protein without pegylation. The Biologics License Application (BLA) of Ryzneuta is currently under late-stage review by the US FDA for Chemotherapy-Induced Neutropenia (CIN)
The CRL did not identify any outstanding scientific issues with the product.
Sun Pharma will receive from Cassiopea the exclusive right to develop and commercialize WINLEVI in Japan, Australia, New Zealand, Brazil, Mexico and Russia.
Sanofi will begin to ship their vaccines helping to ensure more people will be immunized
Silo enters into commercial evaluation license agreement for next generation liposomes
Already an existing partner and supplier of ingredients to Medisca, striking this agreement with SUANFARMA involved reinforcing a well-established symbiotic relationship between two companies committed to world-class quality, service, and price
Infigratinib is not FDA-, Health Canada- or Therapeutics Goods Association-approved for any other indication
Avacc 3 has significant advantages over existing whooping cough vaccines
Subscribe To Our Newsletter & Stay Updated
